Sirbal Ltd.
Records under this name other than the patents Sirbal Ltd. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 3 patents it holds.
Showing 1 to 9 of 9 · Back to Sirbal Ltd.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,344,598 | Herbal nanoformulations for treating psoriasis and other skin conditions Lapsed on the fee record Ended May 31, 2026 · From the USPTO record | Lapsed on the fee record | Ended May 31, 2026 | From the USPTO record |
| US 8,597,695 | Herbal combinations for treatment of a skin condition Lapsed on the fee record Ended Dec 3, 2025 · From the USPTO record | Lapsed on the fee record | Ended Dec 3, 2025 | From the USPTO record |
| US 9,669,062 | Molecular and herbal combinations for treating psoriasis Lapsed on the fee record Ended Jun 6, 2025 · From the USPTO record | Lapsed on the fee record | Ended Jun 6, 2025 | From the USPTO record |
| US 9,662,363 | Molecular and herbal combinations for treating psoriasis Lapsed on the fee record Ended May 30, 2025 · From the USPTO record | Lapsed on the fee record | Ended May 30, 2025 | From the USPTO record |
| US 9,662,364 | Molecular and herbal combinations for treating psoriasis Lapsed on the fee record Ended May 30, 2025 · From the USPTO record | Lapsed on the fee record | Ended May 30, 2025 | From the USPTO record |
| US 9,662,365 | Molecular and herbal combinations for treating psoriasis Lapsed on the fee record Ended May 30, 2025 · From the USPTO record | Lapsed on the fee record | Ended May 30, 2025 | From the USPTO record |
| US 9,662,366 | Molecular and herbal combinations for treating psoriasis Lapsed on the fee record Ended May 30, 2025 · From the USPTO record | Lapsed on the fee record | Ended May 30, 2025 | From the USPTO record |
| US 8,734,859 | Molecular combinations for cancer or other disease treatment Lapsed on the fee record Ended May 27, 2022 · From the USPTO record | Lapsed on the fee record | Ended May 27, 2022 | From the USPTO record |
| US 8,541,382 | Cardiac glycoside analogs in combination with emodin for cancer therapy Lapsed on the fee record Ended Sep 24, 2021 · From the USPTO record | Lapsed on the fee record | Ended Sep 24, 2021 | From the USPTO record |